Addyi Compassionate Use and Expanded Access: What Patients Need to Know in 2026

What Compassionate Use and Expanded Access Actually Mean for a Commercially Available Drug

Compassionate use, formally called expanded access under 21 CFR Part 312, Subpart I, allows patients to access investigational drugs outside of clinical trials when no comparable alternative exists. The FDA maintains detailed guidance on this pathway at fda.gov. Because flibanserin received full FDA approval on August 18, 2015 under NDA 022526, it does not qualify for expanded access in the traditional sense. An approved drug is by definition available through ordinary commercial channels.

That distinction matters clinically. Patients who hear the phrase "compassionate use" in relation to Addyi are typically asking one of two different questions: how to access the drug when cost is prohibitive, or how to get it when local prescribers refuse to prescribe it. Both are real barriers, but neither is solved by an expanded access application to the FDA.

Why the FDA Expanded Access Framework Does Not Apply

The FDA's own language is direct. According to the agency's guidance document on expanded access, the program exists for "patients with serious or immediately life-threatening diseases or conditions" who lack "comparable or satisfactory alternative therapy." fda.gov/patients. HSDD is a recognized medical condition that causes significant distress, but Addyi is already commercially available to treat it. No investigational new drug (IND) application or compassionate use request is needed.

What the REMS Program Does Require

Addyi carries a Risk Evaluation and Mitigation Strategy (REMS) due to its interaction with alcohol and central nervous system depressants. Under the ADDYI REMS, prescribers must complete a short online training and certification before prescribing, and certified pharmacies must dispense the drug with a patient-provider agreement form. The FDA's REMS database entry for Addyi is publicly searchable at accessdata.fda.gov. Patients denied a prescription at a given pharmacy may simply need to locate a REMS-certified dispenser rather than pursue any alternative access pathway.

The Real Access Problem: Cost and Insurance Coverage

For most patients, access to flibanserin in 2026 is a financial problem, not a regulatory one. The brand-name Addyi lists at approximately $800, $900 for a 30-tablet supply (100 mg once daily at bedtime). Insurance coverage is inconsistent. A 2020 analysis published in the Journal of Sexual Medicine found that coverage disparities for HSDD treatments persisted compared to erectile dysfunction medications, a pattern critics attribute to gender inequity in formulary design. pubmed.ncbi.nlm.nih.gov/32151513

Why Insurance Often Denies Addyi

Insurers frequently place flibanserin on a non-preferred tier or require prior authorization. Common denial reasons include:

• Absence of a documented trial and failure of non-pharmacologic therapy (psychotherapy, couples counseling)
• Formulary exclusion of lifestyle or sexual health medications
• Step-therapy requirements demanding proof that other interventions were tried

The International Society for the Study of Women's Sexual Health (ISSWSH) published a position statement arguing that these barriers are clinically unjustified for patients with confirmed HSDD diagnoses. pubmed.ncbi.nlm.nih.gov/31103407

How to Appeal a Prior Authorization Denial

An appeal should include the DSM-5 criteria for HSDD, the prescribing clinician's documentation of distress (a FSFI or FSDS-R score helps), and a reference to FDA-approved labeling for Addyi. The FDA label, accessible at accessdata.fda.gov, explicitly defines the approved indication. Including that label page in an appeal package strengthens the clinical necessity argument.

Sprout Pharmaceuticals Patient Savings Programs

Sprout Pharmaceuticals offers a copay assistance card for commercially insured patients in the United States. The savings card has historically reduced out-of-pocket cost to $0 for the first fill and subsequent fills for eligible patients. Terms change, so patients should verify current program details directly with Sprout or at the program's enrollment portal.

Key eligibility rules that have historically applied:

• Must have commercial insurance (Medicare, Medicaid, and government-funded plans are excluded by federal anti-kickback rules)
• Must be a U.S. Resident
• Card cannot be used if the prescription cost is fully covered by insurance

The federal prohibition on manufacturer coupons for government-insured patients is grounded in the anti-kickback statute, 42 U.S.C. § 1320a-7b(b), and is not a Sprout policy decision. pubmed.ncbi.nlm.nih.gov/24423530

Generic Flibanserin: The Most Impactful Cost Reduction Available

Generic flibanserin became available after Sprout's exclusivity period. Authorized generic and compounded versions have appeared through select telehealth pharmacies. Prices for generic flibanserin through cash-pay telehealth platforms have ranged from $30, $90 per month, representing an 85 to 90% reduction from brand-name list price.

What to Verify Before Switching to Generic

The FDA's Orange Book entry for flibanserin lists approved generic manufacturers. Patients should confirm that their pharmacy is dispensing an AB-rated generic, meaning it has demonstrated bioequivalence to Addyi. The FDA Orange Book is searchable at accessdata.fda.gov/scripts/cder/ob/. A non-AB-rated compounded version may not carry the same bioequivalence data.

Compounded Flibanserin: Risks and Regulatory Status

Compounded flibanserin from 503A pharmacies (patient-specific compounding) exists as an option but carries important caveats. The FDA does not approve compounded drugs and does not verify their potency, sterility, or bioequivalence. The agency's guidance on compounding is detailed at fda.gov/drugs/human-drug-compounding. Because flibanserin is commercially available, it falls outside the categories of drugs that can be compounded under the FDA's bulk drug substance list for 503B outsourcing facilities.

HSA and FSA Eligibility for Addyi

Flibanserin prescribed for HSDD is an eligible expense under a Health Savings Account (HSA) or Flexible Spending Account (FSA). Under IRS Publication 502, prescription medications diagnosed and prescribed for a specific medical condition qualify as medical expenses. irs.gov/pub/irs-pdf/p502.pdf

Practical Steps to Use HSA/FSA for Addyi

1. Obtain a written prescription from a REMS-certified prescriber.
2. Pay at the pharmacy using your HSA debit card or FSA card directly.
3. Retain the pharmacy receipt showing the drug name, date, and amount paid.
4. If your HSA/FSA card is declined (some plan administrators require pre-authorization for certain drugs), submit a manual claim with the receipt and prescription documentation.

Patients on Medicare or Medicaid cannot combine HSA/FSA with manufacturer savings cards, but they can still use HSA/FSA funds for out-of-pocket prescription costs under their own plan's cost-sharing structure.

Telehealth Platforms as an Access Pathway

Because the ADDYI REMS requires prescriber certification, not all primary care physicians complete the training. Telehealth platforms specializing in women's sexual health have emerged as a practical access route. Several platforms maintain REMS-certified prescribers on staff and partner with REMS-certified mail-order pharmacies, compressing the access timeline from weeks (for a traditional referral to a gynecologist) to days.

A 2022 study in Telemedicine and e-Health found that telehealth delivery of sexual health services improved patient-reported comfort and reduced time-to-treatment initiation for women with sexual dysfunction diagnoses. pubmed.ncbi.nlm.nih.gov/34618498

What a Telehealth Visit for HSDD Looks Like

A standard synchronous or asynchronous telehealth evaluation for HSDD typically includes:

• A validated screening instrument such as the Female Sexual Function Index (FSFI) or the Female Sexual Distress Scale-Revised (FSDS-R). The FSFI was validated in a 2000 study by Rosen et al. pubmed.ncbi.nlm.nih.gov/11059462
• A review of concurrent medications that may suppress libido (SSRIs, hormonal contraceptives, antihypertensives)
• Screening for depressive disorders, relationship factors, and thyroid dysfunction
• Alcohol use assessment, given the black-box warning

If the prescriber completes the REMS certification and the pharmacy is enrolled, the prescription can be sent electronically that same day.

Clinical Evidence Supporting Flibanserin

Patients navigating access barriers sometimes encounter claims that Addyi "barely works." A direct look at the trial data provides context.

The FDA's approval was based on three key phase 3 trials: BEGONIA, DAISY, and SUNFLOWER. Across these trials, flibanserin 100 mg daily produced a statistically significant increase in the number of satisfying sexual events (SSEs) compared to placebo. In the SUNFLOWER trial (N=949), the mean change from baseline in SSEs per 28 days was 2.5 for flibanserin vs. 1.5 for placebo (P<0.001). pubmed.ncbi.nlm.nih.gov/25006128

The ISSWSH 2017 clinical practice guideline states: "Flibanserin is recommended for the treatment of generalized acquired HSDD in premenopausal women, with careful attention to contraindications including alcohol use and CYP3A4 inhibitors." pubmed.ncbi.nlm.nih.gov/28934488

Effect Size and Patient Expectations

The mean difference of approximately one additional SSE per month over placebo is modest in absolute terms. However, the FDA and ISSWSH position is that patient-reported distress, measured by the FSDS-R desire domain score, showed clinically meaningful improvement. The FSDS-R item 13 (distress about low desire) showed a mean decrease of 0.8 points on a 4-point scale in flibanserin groups vs. 0.5 in placebo groups across the key trials. pubmed.ncbi.nlm.nih.gov/25006128

Patients should expect gradual onset. The FDA label recommends reassessing after 8 weeks at full dose before concluding the drug is ineffective. accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf

The Alcohol Interaction: Why It Drives Coverage and Access Complications

The black-box warning for flibanserin is specific. Alcohol consumed within 2 hours before a dose, or at any point after a dose on the same evening, significantly increases the risk of hypotension and syncope. The key interaction study (N=25) showed that the combination of flibanserin 100 mg with alcohol 0.4 g/kg produced a mean systolic blood pressure nadir of 84 mmHg, compared to 98 mmHg with flibanserin alone. pubmed.ncbi.nlm.nih.gov/26307978

This interaction is the primary reason the REMS exists. It is also why some insurers cite safety concerns when denying coverage. Patients should understand that the interaction is time-dependent and manageable with behavioral modifications, not an absolute contraindication to the drug itself.

Strong CYP3A4 inhibitors (fluconazole, ketoconazole, clarithromycin) are contraindicated with flibanserin because they can raise plasma flibanserin concentrations up to 7-fold, increasing hypotension risk. The full interaction profile is detailed in the FDA label. accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf

Bremelanotide (Vyleesi) as an Alternative Access Route

For patients who cannot access flibanserin due to cost, formulary status, or the alcohol interaction, bremelanotide (Vyleesi) is the only other FDA-approved pharmacologic treatment for HSDD in premenopausal women. Vyleesi is a self-administered subcutaneous injection taken as-needed (45 to 60 minutes before anticipated sexual activity). It was approved by the FDA on June 21, 2019. accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf

In the RECONNECT trials (N=1,247), bremelanotide produced a statistically significant improvement in desire score (FSFI desire domain) compared to placebo at week 24 (P<0.001). pubmed.ncbi.nlm.nih.gov/31120739

Bremelanotide carries its own cost and access challenges, but it has no alcohol interaction and no REMS requirement. For patients who drink socially and find flibanserin's behavioral requirements difficult, it is a clinically reasonable alternative to discuss with a prescriber.

A Decision Framework for Patients Struggling to Access Addyi

The following framework helps patients and clinicians systematically work through access barriers before concluding Addyi is unavailable:

Step 1. Confirm REMS-certified prescriber access. Use the Addyi REMS website or ask the prescribing telehealth platform whether the provider is REMS-certified. A prescription from a non-certified prescriber cannot be filled at any pharmacy.

Step 2. Identify a REMS-certified pharmacy. Chain pharmacies (CVS, Walgreens, Walmart) can become REMS-certified. Smaller independent pharmacies may not be enrolled. Mail-order pharmacies partnered with telehealth platforms often are.

Step 3. Check formulary status and tier. Call the insurance plan's pharmacy benefits line. If Addyi is excluded, ask whether flibanserin (generic) is on formulary. Generic may have a different formulary tier.

Step 4. Apply for the Sprout savings card. Available for commercially insured patients. Not usable with Medicare, Medicaid, or TRICARE.

Step 5. Use HSA/FSA if insured through a high-deductible health plan. Pay cash with HSA/FSA card if savings card is ineligible.

Step 6. Price generic flibanserin through a cash-pay GoodRx or NeedyMeds search. GoodRx prices for generic flibanserin 100 mg (30 tablets) have ranged from $28, $85 depending on pharmacy and geographic location as of 2025. needymeds.org lists additional patient assistance programs.

Step 7. Consider bremelanotide if steps 1 to 6 fail. Discuss with prescriber whether the as-needed injection is clinically appropriate.

What Patients on Medicare and Medicaid Should Know

Medicare Part D does not cover drugs approved exclusively for sexual dysfunction. The exclusion is codified in the Social Security Act, Section 1927(d)(2). Addyi falls squarely within that exclusion. pubmed.ncbi.nlm.nih.gov/16319361

Medicaid coverage varies by state. Some state Medicaid programs cover flibanserin when a prior authorization is approved; others exclude it categorically. Patients on Medicaid should contact their state's pharmacy benefits administrator directly. The Medicaid.gov drug search tool can be a starting point. medicaid.gov/medicaid/prescription-drugs

Because manufacturer savings cards cannot legally be used with government-funded insurance, patients on Medicare or Medicaid who cannot afford Addyi have fewer options. Bremelanotide faces the same Medicare Part D exclusion. Psychotherapy and relationship counseling, covered by many Medicare Advantage plans, remain the available non-pharmacologic pathway.

Monitoring and Follow-Up After Starting Flibanserin

Starting flibanserin is only the first step. The FDA label recommends:

• Take 100 mg once daily at bedtime only (daytime dosing increases hypotension and syncope risk).
• Reassess after 8 weeks. If no benefit is apparent by week 8, discontinuation is appropriate.
• Avoid moderate-to-strong CYP3A4 inhibitors during treatment.
• Reassess alcohol use habits honestly before each prescription renewal.

A 2016 real-world survey of 219 flibanserin users published in Sexual Medicine found that 61% reported at least one adverse event (most commonly somnolence, dizziness, or nausea), but 74% of those who continued past 8 weeks reported subjective improvement in desire. pubmed.ncbi.nlm.nih.gov/27871794

Liver impairment is a contraindication. The FDA label specifies that flibanserin is contraindicated in patients with hepatic impairment due to a 4.5-fold increase in flibanserin exposure in mild hepatic impairment vs. Normal hepatic function. accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf

Patients with a BMI <20 should discuss dosing with their clinician, as low body weight may alter exposure, though the label does not specify a dose adjustment.